News

Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research spanning 15 different cancers at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, reinforcing the depth and breadth of its oncology development program, leadership in immuno-oncology and commitment to delivering value to patients and health systems by discovering potential options to improve long-term outcomes in cancer patients. The virtual congress will take place from September 19 to 21, 2020.

Presentations will highlight Bristol Myers Squibb’s research aimed at addressing cancer through clinical data evaluating Opdivo (nivolumab)as an adjuvant therapy, Opdivo plus Yervoy (ipilimumab) as a first-line treatment and Opdivo-based combinations across an expanding range of cancer types with the goal of advancing durable therapeutic outcomes for patients in need.

Bristol Myers Squibb will also present data exploring various novel tumor targets in early-stage pipeline therapies and novel combinations in cancers including non-Hodgkin lymphoma, extensive-stage small cell lung cancer, diffuse large B-cell lymphoma and glioblastoma, and nearly 20 presentations will share health economic and real-world research on the clinical and economic impact of Bristol Myers Squibb’s therapies.

Overall, data from more than 67 company-sponsored studies will be presented at the meeting, including 12 late-breaking abstracts and 14 proffered paper presentations. The volume and diversity of these data highlight the role of Bristol Myers Squibb as a company dedicated to transforming the lives of patients with different types of cancer through science.

Key data being presented by Bristol Myers Squibb and its partners at the ESMO Virtual Congress 2020 include:

Renal Cell Carcinoma

First disclosure of detailed Phase 3 CheckMate -9ER efficacy and safety results for Opdivo in combination with Exelixis’ CABOMETYX® (cabozantinib) versus sunitinib in previously untreated advanced renal cell carcinoma (RCC); CheckMate -9ER results will be featured as part of an ESMO Presidential Symposium and in the official Press Programme.
Four-year follow-up from Phase 3 CheckMate -214 study of Opdivo plus Yervoy compared with sunitinib in patients with previously untreated advanced or metastatic RCC; CheckMate -214 represents longest follow-up from a Phase 3 trial of an immunotherapy-based combination in previously untreated advanced RCC.
Gastrointestinal Cancers

First disclosure of Phase 3 CheckMate -577 disease-free survival results for adjuvant Opdivo versus placebo for patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy; CheckMate -577 results will be featured as part of an ESMO Presidential Symposium and in the official Press Programme.
First disclosure of Phase 3 CheckMate -649 overall survival and progression-free survival results for Opdivo plus chemotherapy compared with chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma; CheckMate -649 results will be featured as part of an ESMO Presidential Symposium and in the official Press Programme.
Lung Cancer

Patient-reported outcomes on health-related quality of life from the Phase 3 CheckMate –9LA trial of Opdivo plus Yervoy in combination with two cycles of chemotherapy versus chemotherapy in patients with metastatic advanced non-small cell lung cancer (NSCLC).
Analyses in Asian patients with advanced NSCLC from both CheckMate –9LA and CheckMate-227, which investigated Opdivo plus Yervoy in combination with two cycles of chemotherapy versus chemotherapy and Opdivo plus Yervoy versus chemotherapy as a first-line treatment, respectively.
Melanoma

Four-year results from CheckMate -238 evaluating Opdivo versus Yervoy in adjuvant melanoma and five-year characterizations of complete responses from CheckMate -066, CheckMate -067 and CheckMate -069 studies evaluating Opdivo plus Yervoy or Opdivo alone in advanced melanoma.
“Bristol Myers Squibb has made important progress in demonstrating the significant impact our treatments can have on long-term survival and patient outcomes in numerous cancers,” said Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb. “New data we are presenting at ESMO will highlight the potential to change the standard of care for certain cancers, demonstrate the value our therapies can bring to patients, and showcase how we are defining the future of medicine. We are also grateful for the tireless support from and collaboration with the cancer community, especially from investigators and patients, without whom our research would not be possible.”

Full Story here